Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921128 | 0.80 | MET (0.46) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL21902715 | 0.80 | DYRK1A (0.38) | CLK1DYRK1ADYRK2DYRK1BMAP3K11 | |
| SCHEMBL31228005 | 0.77 | BRD4 (0.54) | CYP2C19CYP2C9CYP3A4CLK1DYRK1A | |
| SCHEMBL91445 | 0.77 | AXL (0.41) | CYP2C19CYP2C9CYP3A4 | |
| SCHEMBL14685266 | 0.77 | CLK1 (0.39) | CYP2C9CYP3A4CLK1DYRK1ADYRK2 | |
| SCHEMBL15154998 | 0.77 | GSK3B (0.56) | CYP2C19CYP2C9CYP3A4MAP3K11 | |
| SCHEMBL1045946 | 0.77 | BRD4 (0.54) | CYP2C19CYP2C9CYP3A4CLK1DYRK1A | |
| SCHEMBL13199598 | 0.77 | CYP3A4 (0.44) | CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL12657249 | 0.77 | JAK2 (0.54) | CYP2C19CYP2C9CYP3A4BRAFCLK1 | |
| SCHEMBL26352450 | 0.77 | CYP3A4 (0.38) | CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | ITPA, POLR2H, POLR2E | CYP2C19 243/4885CYP2C9 1114/4885CYP3A4 1845/4885 |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | ITPA, POLR2H, POLR2E | CYP2C19 243/4885CYP2C9 1114/4885CYP3A4 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.